Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.4%) at 15,601 as of Monday, Aug. 5, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,233 issues advancing vs. 1,686 declining with 120 unchanged. The Health Care sector currently sits up 0.6% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the sector include Valeant Pharmaceuticals International ( VRX), down 1.6%, Vertex Pharmaceuticals ( VRTX), down 1.2%, Shire ( SHPG), down 1.2%, Agilent Technologies ( A), down 1.1% and AstraZeneca ( AZN), down 1.0%. Top gainers within the sector include WellPoint ( WLP), up 2.4%, HCA Holdings ( HCA), up 1.8%, Illumina ( ILMN), up 1.5%, UnitedHealth Group ( UNH), up 1.3% and Aetna ( AET), up 1.2%. TheStreet would like to highlight 5 stocks pushing the sector lower today: 5. Biogen Idec ( BIIB) is one of the companies pushing the Health Care sector lower today. As of noon trading, Biogen Idec is down $1.80 (-0.8%) to $225.96 on light volume. Thus far, 517,532 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $225.10-$229.00 after having opened the day at $228.00 as compared to the previous trading day's close of $227.76. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $52.3 billion and is part of the drugs industry. Shares are up 50.4% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold. TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.